PPT-Optimal treatment for elderly patients with NSCLC

Giorgio V Scagliotti University of Torino Department of Oncology giorgioscagliottiunitoit Key points of the presentation Incidence Age cut off Comorbidity amp . Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. yo. Patient). A 88 . yo. man with hypertension, COPD, . atrial. fibrillation presents with severe CP and is diagnosed with a NSTEMI. He is found to have 90% LAD occlusion and receives a drug eluting stent. Current meds: . actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. May 25, 2013. Mala Joneja, MD MEd FRCPC . Identify factors that contribute to risk in the medical treatment of Rheumatic Diseases in the elderly population. Identify risks associated with specific pharmacological interventions in the elderly. . Michael Shannon, . MD. Endocrinologist . and PSW Medical Director. - Fall Quality Summit Agenda - . Welcome!. . 6:00 – 6:30 Networking & Appetizers . 6:30 – 6:40 Dr. Gary Goin, MD . Introductions . . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD.